Astana Biomed Group, an authorized Abcam distributor in Central Asia

Anti-NR1D1 (phospho S55 + S59) antibody [EPR18346-44] (ab191218)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [EPR18346-44] to NR1D1 (phospho S55 + S59)
  • Suitable for: WB, ELISA
  • Reacts with: Human

Overview

  • Product name

    Anti-NR1D1 (phospho S55 + S59) antibody [EPR18346-44]
    See all NR1D1 primary antibodies

  • Description

    Rabbit monoclonal [EPR18346-44] to NR1D1 (phospho S55 + S59)

  • Host species

    Rabbit

  • Tested Applications & Species

    Application Species
    WB
    Human
    See all applications and species data

  • Immunogen

    Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.

  • Positive control

    • WB: 293T transfected with NR1D1 expression vector containing a GFP-tag®, whole cell lysate

  • General notes

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

    The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing the problem with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation.

    One factor contributing to the crisis is the use of antibodies that are not suitable. This can lead to misleading results and the use of incorrect data informing project assumptions and direction. To help address this challenge, we have introduced an application and species grid on our primary antibody datasheets to make it easy to simplify identification of the right antibody for your needs.

    Learn more here.

Properties

Images

  • Western blot - Anti-NR1D1 (phospho S55 + S59) antibody [EPR18346-44] (ab191218)
    Western blot - Anti-NR1D1 (phospho S55 + S59) antibody [EPR18346-44] (ab191218)
    All lanes : Anti-NR1D1 (phospho S55 + S59) antibody [EPR18346-44] (ab191218) at 1/5000 dilution (Purified)

    Lane 1 : 293T (Human embryonic kidney epithelial cell) transfected with an empty vector (vector control) containing a GFP-tag®, whole cell lysate
    Lane 2 : 293T (Human embryonic kidney epithelial cell) transfected with NR1D1 expression vector containing a GFP-tag®, whole cell lysate
    Lane 3 : 293T (Human embryonic kidney epithelial cell) transfected with NR1D1 expression vector containing a GFP-tag® whole cell lysate,then the membrane treated with Phosphatase for 1 hour

    Lysates/proteins at 15 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution

    Predicted band size: 67 kDa
    Observed band size: 100 kDa
    why is the actual band size different from the predicted?

  • ELISA - Anti-NR1D1 (phospho S55 + S59) antibody [EPR18346-44] (ab191218)
    ELISA - Anti-NR1D1 (phospho S55 + S59) antibody [EPR18346-44] (ab191218)

    Direct ELISA analysis of ab191218 (0-1000 ng/ml) using the following antigens: NR1D1 phospho S55 + phospho S59 peptide, NR1D1 phospho S55 peptide, NR1D1 phospho S59 peptide and NR1D1 unmodified peptide at 1000 ng/ml. An Alkaline Phosphatase-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L) at 1/2500 was used as secondary antibody. 

  • Anti-NR1D1 (phospho S55 + S59) antibody [EPR18346-44] (ab191218)
    Anti-NR1D1 (phospho S55 + S59) antibody [EPR18346-44] (ab191218)

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Alternative products to Anti-NR1D1 (phospho S55 + S59) antibody [EPR18346-44] (ab191218)

© 2021 Astana Biomed Group LLP. All rights reserved.